Scientists Begin Exploring Fungi's Medical Possibilities
T
here is a growing acceptance of psychedelic drugs being used as treatment for various health conditions including depression, panic disorders, post-traumatic stress disorder (PTSD), and opiate addiction.
In addition, such drugs are also used to enhance or change sensory perceptions, energy levels, thought processes, and to facilitate spiritual experiences. Generally, psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens, such as LSD), and those sourced from synthetic processes (human-made) and plants or mushrooms.
Currently, different research studies are underway and are expected to provide a competitive advantage for new and innovative therapeutic manufacturers. And in the United States alone, the psychedelic drugs market is projected to reach a value of USD 6,859.95 Million by 2027 from USD 2,077.90 Million in 2019 while growing with a CAGR of 16.3% in the forecast period of 2020 to 2027, according to Data Bridge Market Research.
Newleaf Brands Inc. (OTC NLBIF) (CSE NLB), Mind Medicine (MindMed) Inc. (OTC MMEDF) (NEO MMED), Champignon Brands Inc. (OTC SHRMF) (CSE SHRM), The Yield Growth Corp. (OTC BOSQF) (CSE BOSS), Dyadic International, Inc. (NASDAQ DYAI)
In recent years, several psychedelic drug product launches and developments were announced and initiated by companies worldwide. For example, in September 2019, Jazz Pharmaceuticals, Inc. had published optimistic data sets from JZP-258's Phase 3 study for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
Data Bridge Market Research indicates that in March 2019, Johnson & Johnson Services, Inc. had received the U.S. Food and drug Administration (FDA) authorization for SPRAVATOTM (esketamine) nasal spray CIII antidepressant for treatment-of resistant depression.
✔️ Scientists Begin Exploring Fungi's Medical Possibilities
💕 Found this article helpful? Spread the word and support us!